# Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

> **NCT01088763** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 129 (actual)

## Conditions studied

- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Ependymoblastoma
- Childhood Grade I Meningioma
- Childhood Grade II Meningioma
- Childhood Grade III Meningioma
- Childhood Infratentorial Ependymoma
- Childhood Medulloepithelioma
- Childhood Mixed Glioma
- Childhood Oligodendroglioma
- Childhood Supratentorial Ependymoma
- Gonadotroph Adenoma
- Pituitary Basophilic Adenoma
- Pituitary Chromophobe Adenoma
- Pituitary Eosinophilic Adenoma
- Prolactin Secreting Adenoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Childhood Spinal Cord Neoplasm
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Childhood Visual Pathway Glioma
- Recurrent Pituitary Tumor
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia
- T-cell Large Granular Lymphocyte Leukemia
- TSH Secreting Adenoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** pharmacological study
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01088763
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088763, "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01088763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*